EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
Pivotal trial more than half enrolled, with completion expected in 2025 Additional Phase I/II functional data expected 1H 2025 Initiating commercial supply manufacturing in Q3 2025 FDA acceptance of ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-reports-second-quarter-2025-financial-results-and-operational-highlights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback